Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Complete Title: An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naive EGFR-mutant Locally Advanced or Metastatic NSCLC
Trial Phase: II
Investigator: Christina Baik
The primary objective of the study is to evaluate the efficacy of osimertinib plus ramucirumab versus osimertinib alone using progression free survival (PFS). Events associated with PFS include: disease progression per RECIST 1.1 and death due to any cause. A total of 150 patients will be enrolled and randomized in a 2:1 fashion (osimertinib plus ramucirumab vs. osimertinib) to the two treatment arms according to the following stratification factors: types of epidermal growth factor receptor (EGFR) mutations and presence of brain metastasis.
Keywords:
- Lung Carcinoma, Non-Small-Cell (NSCLC)
- Metastatic Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
II
Christina Baik
RG1006640
NCT03909334
An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naive EGFR-mutant Locally Advanced or Metastatic NSCLC
Lung Carcinoma, Non-Small-Cell (NSCLC)
Metastatic Solid Tumors